Table 1.
Suggested vedolizumab trough levels33
| Sampling time point | Trough level | Target therapeutic outcome |
| Crohn’s disease | ||
| Induction (w2) | >35.2 | Biological remission (at week 6)43 |
| Induction (w2) | ≥24.5 | No need for dose escalation (at week 24)20 |
| Induction (w6) | ≥18.5 | No need for dose escalation20 |
| Induction (w6) | >27.5 | Sustained clinical response20 |
| Induction (w6) | >18 | Mucosal healing (at week 54)13 |
| Maintenance (w22) | >13.6 | Mucosal healing (at week 22)43 |
| Maintenance (w22) | >12 | Biological remission (at week 22)43 |
| Ulcerative colitis | ||
| Induction (w2) | >28.9 | Clinical response (at week 14)43 |
| Induction (w2) | >23.7 | Mucosal healing (at week 14)43 |
| Induction (w2) | ≥24.5 | No need for dose escalation (at week 24)20 |
| Induction (w6) | >20.8 | Clinical response (at week 14)43 |
| Induction (w6) | ≥18.5 | No need for dose escalation20 |
| Induction (w6) | >27.5 | Sustained clinical response20 |
| Induction (w6) | >18 | Mucosal healing (at week 54)13 |
| Postinduction (w14) | >12.6 | Clinical response (at week 14)43 |
| Postinduction (w14) | >17 | Mucosal healing (at week 14)43 |